Demand stoked by COVID-19 R&D is driving building effort and life sciences business expansion, Danaher’s Biotech Group Executive Emmanuel Ligner tells GEN Edge
Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5 billion expansion of manufacturing capacity planned over the next two years by Cytiva and Pall, the executive overseeing both for parent Danaher told GEN Edge. [Cytiva]
Emmanuel Ligner, group executive, Danaher Biotechnology Group—who is also president and CEO of Cytiva—said the expansion will enable that company and Pall to meet demand for manufacturing across modalities that monoclonal antibodies, recombinant protein, and cell and gene therapy; as well as production basics used in the making of cells such as chromatography resins, cell culture media, and single-use technologies . . .
